Viewing nowBarban Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Palmgen Science Co., Ltd.

MFDS item code 201602325 · Approved 2016.04.26 · Insurance code 670104000
Treatment of essential hypertension, improvement of heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It also helps alleviate symptoms in heart failure patients who cannot use ACE inhibitors and fall under NYHA class II-IV. It is effective in reducing mortality risk in patients with left ventricular dysfunction or systolic dysfunction after myocardial infarction. Overall, this medication assists in managing hypertension and heart-related diseases, improving patient health.
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be coadministered. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years of age or older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients receiving dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following several weeks, the dose should be increased according to patient tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients being treated with other therapies after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients receiving dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of increasing the dose outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant and nursing mothers should not take this medication. It is also unsafe for patients with severely impaired liver function or certain liver diseases. Patients with a history of allergic reactions or angioedema should avoid this medication. Patients with severe renal impairment or certain kidney diseases should also refrain from using it. Caution is advised when using this medication in elderly patients, patients with hyperkalemia, patients with mild liver impairment, and patients with heart valve diseases; blood pressure and renal function should be carefully monitored. When starting treatment, blood pressure may drop sharply, causing dizziness or fainting, so especially patients undergoing dialysis or those on diuretics should start with a low dose and gradually increase it. Caution is required when taking this medication alongside potassium-sparing diuretics or potassium supplements, as it may dangerously raise potassium levels in the blood. When used with non-steroidal anti-inflammatory drugs, the blood pressure-lowering effect may be reduced or renal function may be affected, so it is essential to follow a doctor's guidance. Dizziness may occur while driving or operating machinery, so caution is advisable. The safety and efficacy of this medication have not been established in children and adolescents, hence its use is not recommended. In case of overdose, severe hypotension and altered consciousness may occur, necessitating immediate medical treatment. This medication should be stored out of reach of children, and transferring it to another container should be avoided, as it may not maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.
Light pink, biconvex round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Palmgen Science Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.